Effective vaccination for persons that do not respond to standard Hepatitis B vaccines
Maastricht, The Netherlands, April 29, 2016 / B3C newswire / -- CyTuVax, a life science company focusing on the development of cancer and viral vaccines, today reported the interim results of a phase I clinical trial assessing the safety and efficacy of its lead product, a Hepatitis B HBAI20 vaccine for non-responders. The interim analysis shows that a combination of CyTuVax’s HBAI20 adjuvant and a standard vaccine induced protective anti-Hepatitis B titres after only 2 vaccinations in 60% of true non-responders. This promising result will be extended in a Phase II study in a larger group of true non-responders. The data of the phase I trial will be published in Q3, 2016.
The Hepatitis B HBAI20 vaccine is intended to fulfill a high unmet medical need among persons requiring protective titres against hepatitis B, such as in a medical profession or for travel purposes. True non-responders have received at least 6 vaccinations with a standard vaccine but failed to build up sufficient immune protection against hepatitis B. The trial is conducted at the Ease Travel Clinic by the Department of Medical Microbiology of the MAASTRICHT UMC and coordinated by Dr. A.M. L. Oude Lashof, MD PhD, Internist and Consultant Infectious Diseases of Maastricht UMC.
The trial
The study consists of 3 groups of subjects: 10 true non-responders (no protective anti-Hepatitis B titres after 6 Hepatitis B vaccinations) that were vaccinated with HBAI20 (CyTuVax’s AI20 adjuvant added to HBVaxPro-10 ?g), 12 naïve subjects (volunteers who have never received a hepatitis B vaccination before) that were vaccinated with HBAI20 and 12 naïve subjects that were vaccinated with HBVaxPro 10µg.
Currently, all subjects have been vaccinated twice. In the non-responders group, 60 days after the first vaccination and 30 days after the second vaccination, 60% had protective antibody titres. The adverse events and adverse reactions reported after the first and second vaccination with HBAI20 experimental vaccine were of the number and scale expected for a vaccine and comparable to the HBVaxPro-10µg. There were no serious adverse events reported. The immunogenicity of the HBAI20 is comparable with the immunogenicity of the HBVaxPro-10µg in healthy subjects.
Interim results
This interim analysis shows that the combined AI20/HBVaxPro vaccination induced protective anti-Hepatitis B titres after 2 vaccinations in 60% of true non-responders. This promising result will be extended in a Phase II study in a larger group of true non-responders and a group of persons with renal deficiency, diabetes and transplant recipients.
About Cytuvax
CyTuVax was founded in Maastricht in 2012 by dr. René Vleugels and prof. Frank W. Falkenberg. The company has developed a platform vaccination technology consisting of depot-attached cytokines as immune stimulator (adjuvant).
The vaccination technology has been specifically designed for cancer vaccination therapy. The distinctive feature of CyTuVax’ cancer vaccine is the improved maturation of dendritic cell precursors to CD86+ T-cells and transport of cytokine-micro-aggregates directly into the lymph node, which together forcefully stimulates the activation of T-cells and other immune cells.
The main focus in the field of oncology is on the development of the pancreas cancer vaccine PanCaVax, together with prof. Eric van Cutsem of the University Hospital in Leuven.
CyTuVax is also pursuing the development of viral vaccines. The cytomegalovirus (CMV), which constitutes a major problem in transplant recipients, is another candidate for development into a new vaccine product.
Contacts
CyTuVax B.V.
René Vleugels, CEO
Tel: +31 433881424
Mob: +31 627041717
This email address is being protected from spambots. You need JavaScript enabled to view it.
LifeSpring LifeSciences Communication
Leon Melens
+31 6 538 16427
This email address is being protected from spambots. You need JavaScript enabled to view it.